Pierre Theuma, MD
Endocrinology, Diabetes & Metabolism · Des Moines, IANPI 1982795373
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $345 and has fallen 93.8% since, to $21 in 2025.
Across 37 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$118
- Novo Nordisk$86
- Lilly USA, LLC$75
- Tandem Diabetes Care, Inc.$55
- Medtronic$44
- Amgen$40
- plus $264 from 11 others
What the payments were for
- Food & beverage$681100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 7 | $118 |
| Novo Nordisk | 5 | $86 |
| Lilly USA, LLC | 4 | $75 |
| Tandem Diabetes Care, Inc. | 4 | $55 |
| Medtronic | 1 | $44 |
| Amgen(2 entities) | 2 | $40 |
| Antares Pharma, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Johnson & Johnson | 2 | $36 |
| Nevro Corp. | 1 | $26 |
| Insulet Corporation | 1 | $22 |
| BETA Bionics, Inc. | 1 | $21 |
| AbbVie | 1 | $19 |
| Companion Medical, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$681 in reported general payments places this provider in the 55th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
See all endocrinology, diabetes & metabolism providers in Iowa →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 177 | $209,689 |
| TrulicityDulaglutide | 159 | $187,029 |
| JardianceEmpagliflozin | 222 | $183,358 |
| OzempicSemaglutide | 96 | $121,166 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $121,092 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 101 | $114,737 |
| Humalog Kwikpen U-200Insulin Lispro | 24 | $75,859 |
| Tresiba Flextouch U-100Insulin Degludec | 90 | $59,484 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $56,933 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $43,538 |
| Novolog FlexpenInsulin Aspart | 96 | $41,405 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 74 | $36,283 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $33,400 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 18 | $32,770 |
| FarxigaDapagliflozin Propanediol | 26 | $31,326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $75 | $407,553399 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $17 | $298,094323 claims |
| Novo NordiskOzempic, Tresiba, Novolog | $86 | $143,757153 claims |
| AbbVieSynthroid | $19 | $4,55255 claims |
| Sanofi-aventis U.S. LLCLantus | $37 | $2,07930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
Other endocrinology, diabetes & metabolism in Des Moines
- Anuj BhargavaDes Moines$30K
- Teck KhooDes Moines$6K
- Vanitha SingaramDes Moines$824
- Gurbir GillDes Moines$480
- Pearl DyDes Moines$430
- Daniela MilaniDes Moines$296
- Mary FigaroDavenport$73K
- Ayotunde DokunIowa City$31K
- Marcelo CorreiaIowa City$10K
- Thomas OdorisioIowa City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.